GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Akumin Inc (OTCPK:AKUMQ) » Definitions » Peter Lynch Fair Value

Akumin (Akumin) Peter Lynch Fair Value : N/A (As of May. 17, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Akumin Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Akumin's Peter Lynch Fair Value or its related term are showing as below:



AKUMQ's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.62
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Akumin Peter Lynch Fair Value Historical Data

The historical data trend for Akumin's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akumin Peter Lynch Fair Value Chart

Akumin Annual Data
Trend Sep15 Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - -

Akumin Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Akumin's Peter Lynch Fair Value

For the Diagnostics & Research subindustry, Akumin's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akumin's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Akumin's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Akumin's Price-to-Peter-Lynch-Fair-Value falls into.



Akumin Peter Lynch Fair Value Calculation

Akumin's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *-1.257
=N/A

Akumin's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.26.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Akumin  (OTCPK:AKUMQ) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Akumin's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=0.375/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akumin Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Akumin's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Akumin (Akumin) Business Description

Traded in Other Exchanges
Address
8300 West Sunrise Boulevard, Plantation, FL, USA, 33322
Akumin Inc is a Canada-based company that provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. The company operates in Florida, Pennsylvania, Delaware, Texas, Illinois, and Kansas. It offers physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, minimizing the cost and amount of care for patients. The company's imaging procedures include MRI, CT, positron emission tomography, ultrasound, X-ray, mammography, and other diagnostic or interventional radiology procedures. It operates in two reportable business segments: radiology and oncology. The radiology segment acconts for majority revenue.
Executives
Ronald J. Bienias officer: Chief Restructuring Officer C/O AKUMIN INC.,, 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Stonepeak Gp Investors Holdings Manager Llc 10 percent owner, other: See Remarks 55 HUDSON YARDS, 550 WEST 34TH STREET, 48TH FLOOR, NEW YORK NY 10001
Stonepeak Gp Investors Upper Holdings Lp 10 percent owner, other: See Remarks 55 HUDSON YARDS, 550 WEST 34TH STREET, 48TH FLOOR, NEW YORK NY 10001
Stonepeak Gp Investors Holdings Lp 10 percent owner, other: See Remarks 55 HUDSON YARDS, 550 WEST 34TH STREET, 48TH FLOOR, NEW YORK NY 10001
Krishna Kumar officer: See remarks C/O AKUMIN INC., 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Lawrence Ross Sinclair director 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
R. David Kretschmer officer: See Remarks 310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Murray Lee director 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Scw Capital Management, Lp 10 percent owner 3131 TURTLE CREEK BLVD., SUITE 302, DALLAS TX 75219
Trinity Investment Group, Llc 10 percent owner 3131 TURTLE CREEK BLVD., #302, DALLAS TX 75219
Robert N. Cathey 10 percent owner 3131 TURTLE CREEK BLVD., #302, DALLAS TX 75219
John R. Wagner 10 percent owner 3838 OAK LAWN AVE., SUITE 450, DALLAS TX 75219
Paul Nelis officer: Chief Information Officer 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Haichen Huang director 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322
Matt Cameron officer: See Remarks 8300 W. SUNRISE BOULEVARD, PLANTATION FL 33322